- Home
- BBAI vs OPT Comparison
BBAI vs OPT Comparison
Compare BBAI & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAI
- OPT
- Stock Information
- Founded
- BBAI 2020
- OPT 1984
- Country
- BBAI United States
- OPT Australia
- Employees
- BBAI N/A
- OPT N/A
- Industry
- BBAI EDP Services
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BBAI Technology
- OPT Health Care
- Exchange
- BBAI Nasdaq
- OPT Nasdaq
- Market Cap
- BBAI 716.7M
- OPT 767.9M
- IPO Year
- BBAI N/A
- OPT 2020
- Fundamental
- Price
- BBAI $3.04
- OPT $3.34
- Analyst Decision
- BBAI Buy
- OPT Strong Buy
- Analyst Count
- BBAI 4
- OPT 1
- Target Price
- BBAI $3.17
- OPT $12.00
- AVG Volume (30 Days)
- BBAI 46.2M
- OPT 12.3K
- Earning Date
- BBAI 11-05-2024
- OPT 08-30-2024
- Dividend Yield
- BBAI N/A
- OPT N/A
- EPS Growth
- BBAI N/A
- OPT N/A
- EPS
- BBAI N/A
- OPT N/A
- Revenue
- BBAI $154,972,000.00
- OPT $261,859.00
- Revenue This Year
- BBAI $13.47
- OPT N/A
- Revenue Next Year
- BBAI $16.32
- OPT $46,864.64
- P/E Ratio
- BBAI N/A
- OPT N/A
- Revenue Growth
- BBAI 0.01
- OPT N/A
- 52 Week Low
- BBAI $1.17
- OPT $1.79
- 52 Week High
- BBAI $4.80
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- BBAI 52.81
- OPT 43.16
- Support Level
- BBAI $2.42
- OPT $3.15
- Resistance Level
- BBAI $3.82
- OPT $3.39
- Average True Range (ATR)
- BBAI 0.57
- OPT 0.18
- MACD
- BBAI -0.04
- OPT -0.00
- Stochastic Oscillator
- BBAI 27.85
- OPT 27.49
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.